Lates News

Every AI newsflash, Huaan Securities released a research report on September 4th, giving Tiankang Biotechnology (002100.SZ) a "buy" rating. The main reasons for the rating include: 1) The net profit attributable to shareholders in the first half of 2025 was 338 million yuan, and the debt-to-asset ratio decreased to 47% at the end of June; 2) The target for 2025 is expected to be achieved smoothly, with the cost of self-breeding and self-breeding in the first half of 2025 reduced to 12.55 yuan; 3) The company plans to acquire Qangdu Livestock with cash, which has outstanding performance in pig farming and a good historical performance. (Daily Economic News)